IBS-C Treatment Zelnorm Withdrawn From the Market Again
The decision to remove Zelnorm from the market was strictly a business decision.
Diagnosis & Disease Information
Ibsrela Now Available for Irritable Bowel Syndrome With Constipation
The approval was based on two phase 3 trials which evaluated Ibsrela in over 1200 adults with IBS-C.
Factors Associated With Nonresponse to FMT Identified in IBS
Among those with irritable bowel syndrome, men and/or those with low Alistipes levels more likely to be nonresponders
Open-Label Placebo Studied in Children With Abdominal Pain, IBS
Open-label placebo may contribute to therapeutic effect in children and adolescents with functional abdominal pain, irritable bowel syndrome
Prescription Digital Therapeutic Cleared for IBS-Associated Abdominal Pain
Regulora is designed to provide seven 30-minute sessions of remote behavioral therapy based on gut-directed hypnotherapy.
Linzess Labeling Updated Based on New Pediatric Data
The updated label now states that the treatment is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.
Ultra-Processed Food May Up Risk for Inflammatory Bowel Disease
Higher risk for developing IBD associated with higher intake of ultra-processed foods, such as soft drinks, salty snacks, processed meat
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
Generic Version of Amitiza Now Available
The Company has begun shipping both the 8mcg and 24mcg capsules; the capsules are supplied in 60-count bottles.
MPR Weekly Dose Podcast Episode 39
This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders.
